Para publicación inmediata - 9 de marzo de 2010

Seneffe, Bélgica, 9 de marzo de 2010. IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) ha anunciado hoy que, tras los recientes desarrollos, el período de aceptación para la oferta pública de adquisición lanzada por Eckert & Ziegler AG y SMI Steglitz Medinvest sobre el conjunto de los títulos IBt se prolonga hasta el 17 de marzo de 2010 a las 16 h.

Acerca de IBt Bebig
... Contributing to saving lives!

IBt Bebig es un grupo europeo activo en el segmento de los dispositivos médicos dentro del sector sanitario.

The core business of the IBt Bebig group is the cancer treatment by radiation technology. Its specificity is the treatment of cancer by brachytherapy, a technique which consists of placing a sealed implant containing a minuscule quantity of a radioactive isotope in the body, on either a temporary or on a permanent basis. Depending on the application, the implant can take the shape of a plaque, a seed or a catheter. The precise positioning of the implant allows the cancer cells to be destroyed while sparing the healthy tissues and increasing the patient's quality of life. Today, the alternative brachytherapy procedures cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers.

The IBt Bebig group employs over 150 people and has entities in Germany, France, United Kingdom, Spain, Italy and India. Its Head Office is located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH.BR - Bloomberg : IBTB BB).

Contact
Paul-Emmanuel Goethals
Head of Investor Relations & Communication
Tel: +32.64.520.808

E-mail: ir@ibt-bebig.eu
Internet: www.ibt-bebig.eu


Copyright Hugin

Este anuncio fue transmitido por Hugin. El emisor es el único responsable del contenido.

[CN#163959]